摘要
目的:探讨左乙拉西坦辅治对小儿热性惊厥患者脑神经相关因子及复发的影响。方法:选取2015年1月-2016年3月在笔者所在医院进行治疗的热性惊厥患者94例,按随机数表法分为观察组和对照组,各47例。对照组行常规治疗,观察组在对照组基础上加用左乙拉西坦辅助治疗,比较两组脑神经相关因子、免疫功能指标及复发和癫痫转化情况。结果:治疗6个月后,观察组血清神经元特异性烯醇化酶、S-100β蛋白、脑源性神经营养因子水平分别为(8.28±1.78)μg/L、(0.12±0.01)μg/L、(6.75±0.61)μg/L,均明显低于对照组,差异均有统计学意义(t=4.215、36.855、23.527,P<0.05)。观察组CD8^+、免疫球蛋白A、IgM、IgG水平分别为(16.85±1.54)%、(0.53±0.06)g/L、(0.64±0.05)g/L、(6.12±0.61)g/L,均低于对照组;CD4^+、CD4^+/CD8^+分别为(42.83±2.80)%、(2.18±0.21),均高于对照组,差异均有统计学意义(t=15.360、22.339、23.112、13.549、7.133、11.137,P<0.05)。观察组复发率及复发惊厥平均时间分别为2.13%、(1.65±1.73)min,均低于对照组,差异均有统计学意义(X^2=4.424、t=12.089,P<0.05)。结论:左乙拉西坦辅治可有效降低热性惊厥患儿脑神经相关因子水平,提高机体免疫功能,降低复发率。
Objective：To investigate the effect of Levetiracetam on brain-related nerve factor and recurrence in children with febrile convulsion.Method：A total of 94 cases of febrile convulsion treated in the author＇s hospital from January 2015 to March 2016 were selected,and they were divided into observation group and control group by random number table,with 47 cases in each group.Control group was given routine treatment,while observation group was treated with Levetiracetam based on control group.The brain-related nerve factor,indexes of immune function,recurrence and epilepsy transformation were compared between the two groups.Result：After six-month treatment,the levels of neuron-specific enolase,S-100β protein,brain-derived neurotrophic factor in observation group were（8.28±1.78）μg/L,（0.12±0.01）μg/L,（6.75±0.61）μg/L,were lower than those in control group,the differences were statistically significant（t=4.215,36.855,23.527,P0.05）.The levels of CD8~＋,immunoglobulin A,IgM,IgG in observation group were（16.85±1.54）%,（0.53±0.06）g/L,（0.64±0.05）g/L,（6.12±0.61）g/L,were lower than those in control group,the levels of CD4~＋,CD4~＋/CD8~＋ in observation were（42.83±2.80）%,（2.18±0.21）,were higher than those in control group,the differences were statistically significant（t=15.360,22.339,23.112,13.549,7.133,11.137,P0.05）.The recurrence rate and average time of recurrent convulsion in observation group were 2.13%,（1.65±1.73）min,were less than those in control group,the differences were statistically significant（X^2 =4.424,t=12.089,P0.05）.Conclusion：Levetiracetam in treatment of children with febrile convulsion can decrease the levels of brain-related nerve factors,increase immune function and reduce the recurrence rate.
出处
《中外医学研究》
2018年第1期3-5,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
左乙拉西坦
小儿热性惊厥
脑神经相关因子
复发
Levetiraeetam
Children with febrile convulsion
Brain-related nerve factor
Recurrence
